MY180331A - Nootropic "pantocalcin" in liquid form - Google Patents
Nootropic "pantocalcin" in liquid formInfo
- Publication number
- MY180331A MY180331A MYPI2016001359A MYPI2016001359A MY180331A MY 180331 A MY180331 A MY 180331A MY PI2016001359 A MYPI2016001359 A MY PI2016001359A MY PI2016001359 A MYPI2016001359 A MY PI2016001359A MY 180331 A MY180331 A MY 180331A
- Authority
- MY
- Malaysia
- Prior art keywords
- owing
- liquid form
- nootropic
- viscosity
- pantocalcin
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 3
- 230000001777 nootropic effect Effects 0.000 title abstract 2
- SBBDHANTMHIRGW-QMMMGPOBSA-N hopantenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCC(O)=O SBBDHANTMHIRGW-QMMMGPOBSA-N 0.000 title 1
- 229950001260 hopantenic acid Drugs 0.000 title 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a pharmaceutical product exhibiting nootropic properties of mixed type , having a wide spectrum of action influencing the GABA (gamma-aminobutyric acid) system, and may be used in medicine is psychoneurological practice and in the pharmaceutical industry. The technical effect of the invention is a hopantenate formulation in the form of drops as well as an increase of the active substance content (up to 40%) of the liquid preparation due to improvement of its organoleptic property and provision of the possibility of lowering viscosity of the preparation liquid form owing to decreasing an amount of substances raising its viscosity and owing to increasing its water content.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014101564/15A RU2542419C1 (en) | 2014-01-20 | 2014-01-20 | Pantocalcin, nootropic agent in liquid form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY180331A true MY180331A (en) | 2020-11-28 |
Family
ID=53289006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2016001359A MY180331A (en) | 2014-01-20 | 2015-01-16 | Nootropic "pantocalcin" in liquid form |
Country Status (6)
| Country | Link |
|---|---|
| CN (1) | CN105979931A (en) |
| EA (1) | EA027991B1 (en) |
| MY (1) | MY180331A (en) |
| RU (1) | RU2542419C1 (en) |
| UA (1) | UA113822C2 (en) |
| WO (1) | WO2015108449A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2703293C1 (en) * | 2018-11-06 | 2019-10-16 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Liquid dosage form for oral administration, having nootropic activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2145213C1 (en) * | 1999-05-25 | 2000-02-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Pharmaceutical composition exhibiting nootropic effect and method of its preparing |
| RU2181757C2 (en) * | 2000-03-07 | 2002-04-27 | Тюменская государственная медицинская академия | Lipid stabilization composition |
| RU2177783C1 (en) * | 2001-02-02 | 2002-01-10 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Nootropic preparation |
| EP2050438B1 (en) * | 2006-07-26 | 2016-10-19 | Asahi Kasei Kabushiki Kaisha | Spherical crude granule and method for production thereof |
-
2014
- 2014-01-20 RU RU2014101564/15A patent/RU2542419C1/en active
-
2015
- 2015-01-16 CN CN201580005035.7A patent/CN105979931A/en active Pending
- 2015-01-16 MY MYPI2016001359A patent/MY180331A/en unknown
- 2015-01-16 WO PCT/RU2015/000014 patent/WO2015108449A1/en active Application Filing
- 2015-01-16 EA EA201691206A patent/EA027991B1/en unknown
- 2015-01-16 UA UAA201607849A patent/UA113822C2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA027991B1 (en) | 2017-09-29 |
| WO2015108449A1 (en) | 2015-07-23 |
| UA113822C2 (en) | 2017-03-10 |
| EA201691206A1 (en) | 2016-09-30 |
| RU2542419C1 (en) | 2015-02-20 |
| CN105979931A (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4309643A3 (en) | Viscosity-reducing excipient compounds for protein formulations | |
| SA521422031B1 (en) | 2-Formyl-3-Hydroxyphenyloxymethyl Compounds Capable of Modulating Hemoglobin | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| SA519401239B1 (en) | Amylin Analogues | |
| PH12017501674A1 (en) | Amylin analogues | |
| MX370450B (en) | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator. | |
| WO2012016201A3 (en) | Process for modifying the properties of citrus fiber | |
| MX2019001903A (en) | Compositions and methods for modulating gastrointestinal microflora in a canine. | |
| EA201692007A1 (en) | IZOINDOLINON COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA, AND RELATED DISORDERS | |
| MX2016013029A (en) | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders. | |
| EA201791531A1 (en) | NATURAL SPREADER | |
| WO2015171460A3 (en) | Formulations of cyclophosphamide liquid concentrate | |
| BR112015027540A2 (en) | liquid resin fatty acid | |
| MX2017004772A (en) | Compositions and methods for physiological delivery using cannabidiol. | |
| WO2017037075A8 (en) | Composition containing echinacea extract and linoleic acid derivatives | |
| MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| PH12016500414A1 (en) | Solid preparation containing choline alfoscerate and method for preparing same | |
| EP3295932A3 (en) | Stable odf composition containing hardly soluble therapeutic agent | |
| WO2012152940A3 (en) | Small molecule inhibitors of trpa1 | |
| NZ756986A (en) | Health food and cosmetics for increasing the amount of apoptosis cells and decreasing the amount of necrosis cells and a method of manufacturing a sprout-forcing grape seed-derived ingredient for increasing the amount of apoptosis cells and decreasing the amount of necrosis cells | |
| MY180331A (en) | Nootropic "pantocalcin" in liquid form | |
| EA201890511A1 (en) | HYDROGEN WATER WITH ENHANCED ANTIOXIDANT ACTIVITY AND METHODS FOR ITS PREPARATION | |
| WO2016195194A3 (en) | Novel tlr2 antagonists | |
| MD20140110A2 (en) | Medicinal agent for the treatment of mastitis in bovine animals and preparation process thereof | |
| MX2017006747A (en) | Fatty acid amides for the prevention and/or treatment of steatohepatitis. |